Navigation Links
CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
Date:5/31/2011

SEOUL, South Korea, May 31, 2011 /PRNewswire/ -- CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, California), a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis (OA).

CG100649 is a first-in-class NSAID drug candidate that is a dual inhibitor of COX-2 and carbonic anhydrase (CA). CG100649's interaction with carbonic anhydrase in red blood cells provides it with a novel "tissue-specific" transport mechanism that is designed to deliver sustained levels of drug to inflamed tissues, while maintaining low systemic exposure. Its unique dual COX-2 and CA binding properties are designed to provide potentially superior safety to cardiovascular, renal, and gastrointestinal tissues compared to traditional NSAIDs or COX-2 inhibitor drugs.

An earlier placebo-controlled Phase 2a efficacy study in hip and knee in 248 OA patients in Europe showed that a 1.2 mg daily dose provided a highly significant efficacy profile vs. the three major OA symptoms of pain, stiffness, and physical disability.  Although this was not an active-comparator trial, the efficacy profile of CG100649 appeared to be at least as favorable as other COX-2 drugs. This prompted CrystalGenomics to conduct a supra-threshold Phase 1 Multiple Ascending Dose (MAD) study in healthy subjects last year that showed that higher doses of CG100649 (2, 4, or 8 mg per day) are likely to provide even higher levels of efficacy while maintaining CG100649's favorable safety profile.

The current Phase 2b study is a double-blind, randomized, multicenter, non-inferiority, repeat dose study of CG100649 versus celecoxib (Celebrex®) in OA patients. This is the first time that the OA efficacy of CG100649 is being tested directly against celecoxib in the same clin
'/>"/>

SOURCE CrystalGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Metabolex Initiates Phase 2 Trial of Arhalofenate
2. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
3. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
4. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
5. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
6. Stephens Initiates Coverage on Vermillion
7. Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
8. American Regent Initiates Voluntary Nationwide Recall of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Single Dose Vials; 5 mL and 30 mL Multiple Dose Vials
9. CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
10. Max Neeman International Initiates Advisory Committee to Advance and Improve the Conduct of Complex Neurological Trials in India
11. Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... GLOBAL MARKETS , that the global market RNA interference ... nearly $38.8 billion by 2018, with a five-year compound ... category, the fastest moving segment of the market, is ... of RNAi therapeutics has shown tremendous growth and has ...
(Date:8/1/2014)... Aug. 1, 2014 Glencoe Software, ... of "Data InPress" ( http://glencoesoftware.com/data-inpress.html ), a ... multidimensional image data into on-line publications.  The ... Video Injection Service. Photo - ... http://photos.prnewswire.com/prnh/20140731/132409 The DataViewer ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Food ... are increasingly searching for food alternatives that offer ... benefits. The food ingredient market has numerous players ... such as Vital Force Technology (VFT). VFT ... than 4,000 energetic patterns, all tested to produce ...
(Date:7/31/2014)... , the leading life sciences employment and news website, launched the ... Illinois , Indiana , ... , Minnesota , Missouri , ... Wisconsin . BioMidwest is a leader in biotech and ... in this region in 2013. The life sciences sector in this area ...
Breaking Biology Technology:Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Glencoe Software Launches Data InPress 2Glencoe Software Launches Data InPress 3Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2Midwest Biotech Leaders Featured On BioSpace Map 2
... Systems International (OTCBB: IFRS) subsidiary, AquaLiv, Inc., has ... Technology. AquaLiv received an overwhelming number ... of its recent announcement that its pilot HIV/AIDS ... on any active molecule. According to the announcement, ...
... 2011 PharmaNet Development Group, Inc. (the "Company" or "PharmaNet") ... and consent solicitation (the "Offer") for any and all of ... "Notes"), it has elected to extend the consent payment deadline ... on June 10, 2011, unless extended or earlier terminated (the ...
... of Mechanical Engineering at Stevens Institute of Technology, ... Roster as a candidate for grants to cooperate ... Department of State, the Fulbright Specialist Program places ... collaborations that strengthen the positions of US institutions. ...
Cached Biology Technology:Infrared Systems International's Subsidiary, AquaLiv Inc., Explains Its Revolutionary Technology in Layman's Terms 2Infrared Systems International's Subsidiary, AquaLiv Inc., Explains Its Revolutionary Technology in Layman's Terms 3PharmaNet Extends Consent Payment Deadline for Notes Tendered in Its Tender Offer and Consent Solicitation 2PharmaNet Extends Consent Payment Deadline for Notes Tendered in Its Tender Offer and Consent Solicitation 3PharmaNet Extends Consent Payment Deadline for Notes Tendered in Its Tender Offer and Consent Solicitation 4Dr. Frank Fisher of Stevens selected for Fulbright specialist roster 2
(Date:8/1/2014)... New Rochelle, NY, August 1, 2014Lesbian, gay, bisexual, and ... face the same problems as some of their heterosexual ... addition they often face additional physiological and legal ... most recent advances in assisted reproduction options is presented ... and Future Possibilities ," published in LGBT ...
(Date:8/1/2014)... INDIANAPOLIS, IN August 1, 2014 The Journal ... Best Article and Best Great Educational Material (GEM) awards, ... and Behavior (SNEB) annual conference, "Nutrition Education Impact: Local ... 1, 2014. These annual awards recognize the authors ... year in JNEB, as judged by members of the ...
(Date:8/1/2014)... new study, including two Simon Fraser University research ... and policymakers must collaborate closely on minimizing damage ... Viorel Popescu and Maureen Ryan, David H. Smith ... are among eight international co-authors of the newly ... the Environment . , Shale gas development is ...
Breaking Biology News(10 mins):Advances in assisted reproduction create more options & new legal issues for LGBT couples 2Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3
... PHOENIX, Ariz. Sept. 1, 2008 Researchers at ... new approach to treating endometrial cancer patients that not ... cancer cells. In a potentially major breakthrough, TGen ... in St. Louis discovered that introducing a particular inhibitor ...
... likely to die of - heart disease compared with women ... blame, according to a new University of Leicester led study ... New Blood Lecturer in Cardiovascular Medicine in the Department of ... "male disadvantage" may be related to the sex-specific effects of ...
... that increase the risk of developing inflammatory bowel disease ... to identify the specific disease-causing mutations in these new ... candidates to be added to the list of genes ... find genes that interact with each other and with ...
Cached Biology News:TGen and Washington University researchers discover new approach to treating endometrial cancer 2TGen and Washington University researchers discover new approach to treating endometrial cancer 3Sex hormones link to heart risk 2New genes found for inflammatory bowel disease in children 2New genes found for inflammatory bowel disease in children 3
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Validated and Silencer Pre-designed siRNAs, ...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Biology Products: